The Impact of Innovative Activities in the Innovative Pharmaceutical Industry on Corporate Market Value

Tianzhou Jiang

doi:10.54097/8qmby127

Authors

Tianzhou Jiang

DOI:

https://doi.org/10.54097/8qmby127

Keywords:

Innovative drugs, Innovative drug market research, Enterprise market value, Corporate financial management.

Abstract

Innovative drugs refer to drugs with independent intellectual property patents. With the gradual improvement of China's intellectual property status, research on innovative drugs will bring high profits to enterprises. The innovative drug industry has always been in the eyes of investors in today's social conditions. At the same time, as an emerging investment option, what indicators will affect the changes in the market value of innovative drug companies is available for everyone to discuss. In this article, through the collection of Chinese innovation Companies in the pharmaceutical industry conducted linear regression analysis and found that the impact of corporate market value is closely related to innovation activities. At the same time, it was found that patent activities related to innovation activities will have a marginal effect and have a certain negative correlation. This article aims to help companies in the innovative drug industry find ways to increase their market value and help investors see the good news brought about by innovative activities in the stock market.

Downloads

Download data is not yet available.

References

Fernando J. Market Capitalization: What it means for investors [EB/OL]. Investopedia.2024-03-05. https://www.investopedia.com/terms/m/marketcapitalization.asp.

Chen Y, Chang K-C. The relationship between a firm’s patent quality and its market value — The case of the US pharmaceutical industry [J]. Technological Forecasting and Social Change, 2010, 77 (1): 20–33.

Gök O, Peker S. Understanding the links among innovation performance, market performance and financial performance [J]. Review of Managerial Science, 2016, 11 (3): 605–631.

Neng-Kun Z, Yu H, Yong-Ji Z. A study of M&A and innovation of listed Chinese pharmaceutical companies [EB/OL]. 2019-02-20. https://www.kygl.net.cn/EN/abstract/abstract11677.shtml.

Marques C M, Moniz S, De Sousa J P, et al. Decision-support challenges in the chemical-pharmaceutical industry: Findings and future research directions [J]. Computers & Chemical Engineering, 2020, 134: 106672.

Rubera G, Kirca A H. Firm Innovativeness and its Performance Outcomes: a Meta-Analytic Review and Theoretical integration [J]. ResearchGate, 2012.

Hai B, Yin X, Xiong J, et al. Could more innovation output bring better financial performance? The role of financial constraints [J]. Financial Innovation, 2022, 8 (1).

IFPMA. #AlwaysInnovating: The importance of pharmaceutical innovation – IFPMA [EB/OL]. IFPMA.2023-08-24.https://www.ifpma.org/insights/alwaysinnovating-the-importance-of-pharmaceutical-innovation/.

The next horizon of innovation for pharma [EB/OL]. McKinsey & Company. 2017-03-22. https://www.mckinsey.com/industries/life-sciences/our-insights/the-next-horizon-of-innovation-for-pharma.

Zs. A coming (r)evolution? Pharma industry outlook, trends and strategies for 2024 [EB/OL]. 2024-02-13. https://www.zs.com/insights/trends-shaping-pharmaceutical-landscape-2024-and-beyond.